Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News AstraZeneca ADR Representing 0.5 Ord Shs AZN

Consumer Cyclical Healthcare Advertising Agencies
AstraZeneca PLC is a science-led biopharmaceutical company. It discovers, develops, and commercializes prescription medicines in oncology, rare diseases, and biopharmaceuticals, including cardiovascular, renal and metabolism, respiratory and immunology and vaccines and immune therapies. Its key marketed oncology products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Zoladex... see more

Recent & Breaking News (NDAQ:AZN)

FARXIGA Granted Breakthrough Therapy Designation in US for Chronic Kidney Disease

Business Wire October 2, 2020

LYNPARZA® (olaparib) Reduced the Risk of Death by 31% in BRCA1/2 or ATM-mutated Metastatic Castration-Resistant Prostate Cancer in Phase III Profound Trial

Business Wire September 20, 2020

TAGRISSO Reduced the Risk of Disease Recurrence in the Brain by 82% in the Adjuvant Treatment of Early-Stage EGFR-Mutated Lung Cancer

Business Wire September 19, 2020

LYNPARZA® (olaparib) Improved Median Time Patients Lived Without Disease Progression to Over Four and Half Years in BRCA-mutated Advanced Ovarian Cancer vs. Just Over One Year With Placebo

Business Wire September 18, 2020

IMFINZI Demonstrated Unprecedented Survival in Unresectable Stage III Non-small Cell Lung Cancer With an Estimated 50% of Patients Surviving Four Years

Business Wire September 18, 2020

Can Tech Build a Comeback During this Market Slump?

Stockhouse Editorial September 9, 2020

Futures Recover after NASDAQ Correction

Livemoney September 9, 2020

Biopharma Leaders Unite to Stand with Science

GlobeNewswire September 8, 2020

Development of COVID-19 Vaccine AZD1222 Expands Into US Phase III Clinical Trial Across All Adult Age Groups

Business Wire August 31, 2020

FARXIGA Demonstrated Unprecedented Reduction in the Risk of Kidney Failure and Cardiovascular or Renal Death in Patients with Chronic Kidney Disease in the Phase III DAPA-CKD Trial

Business Wire August 30, 2020

RenalytixAI to Collaborate with AstraZeneca to Improve Outcomes for Patients with Chronic Disease

GlobeNewswire August 21, 2020

AstraZeneca Ships FLUMIST® QUADRIVALENT Vaccine in the US for 2020-2021 Flu Season

Business Wire August 13, 2020

RedHill Biopharma Provides Q2/2020 Financial Results and Operational Highlights

GlobeNewswire August 13, 2020

AstraZeneca Partners with Actor and Author Tony Hale to Build Awareness of Eosinophilic Asthma and How Not All Asthma is the Same

Business Wire August 11, 2020

TAGRISSO Granted Breakthrough Therapy Designation in the US for the Adjuvant Treatment of Patients With Stage IB-IIIA EGFR-mutated Lung Cancer

Business Wire July 30, 2020

FARXIGA Met All Primary and Secondary Endpoints in Groundbreaking Phase III DAPA-CKD Trial for the Treatment of Patients With Chronic Kidney Disease

Business Wire July 28, 2020

Chi-Med's NDA for Savolitinib in Non-Small Cell Lung Cancer Granted Priority Review in China

GlobeNewswire July 28, 2020

BREZTRI AEROSPHERE approved in the US for the maintenance treatment of COPD

Business Wire July 24, 2020

FARXIGA Granted Fast Track Designation in the US for Heart Failure Following Acute Myocardial Infarction Leveraging an Innovative Registry-Based Trial Design

Business Wire July 16, 2020

BRILINTA Significantly Reduced the Rate of the Composite of Stroke and Death in Patients Who Had an Acute Ischemic Stroke or Transient Ischemic Attack in the Phase III THALES Trial

Business Wire July 16, 2020